Palvella Therapeutics PVLA
NASDAQ PVLA
$155.76 +0.29 (+0.19%)
As of: Sep 4, 2026 · 3:12 PM EDT

Palvella Therapeutics (PVLA) Non Operating Interest Expenses (2014 - 2024)

Analysis

Palvella Therapeutics (PVLA) Non Operating Interest Expenses (2014 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Palvella Therapeutics 2.24 Bn 1.92 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 181,000.00
Sep 30, 2024 220,000.00
Jun 30, 2024 29,000.00
Jun 30, 2015 53.00
Mar 31, 2015 4,170.00
Jun 30, 2014 223,083.00
Mar 31, 2014 109,289.00